Aethlon Medical Inc (AEMD) Stock Price & Analysis
Aethlon Medical Inc (AEMD) fell 4.43% to USD 1.94 as of June 10, 2026 at 04:26 UTC, according to Nexqual real-time market data.
AEMD last closed at USD 2.03; the session ranged USD 1.94–2.1 on volume of 129,594 shares. Market capitalization is $4.55M, with a 52-week range of USD 1.36–27.4 (NCM). Source: Nexqual, June 10, 2026 at 04:26 UTC.
Key Statistics (as of June 10, 2026 at 04:26 UTC)
| Price | USD 1.94 |
|---|---|
| Change | ▼ 4.43% (down) |
| Previous Close | USD 2.03 |
| Open | USD 2.01 |
| Day Range | USD 1.94 – 2.1 |
| 52-Week Range | USD 1.36 – 27.4 |
| Volume | 129,594 shares |
| Market Cap | $4.55M |
| Exchange | NCM |
Technical Analysis (AEMD)
Nexqual's technical model rates AEMD "SELL" based on 1 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 04:26 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 43.98 (neutral) |
| vs SMA50 | Below (USD 2.24) |
| MACD | -0.03 (negative) |
Analyst Ratings (AEMD)
Wall Street analysts rate AEMD "None" based on 2 analysts, with a mean price target of USD 4.75 (range USD 1.5–8), per Nexqual as of June 10, 2026 at 04:26 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 4.75 |
| High Target | USD 8 |
| Low Target | USD 1.5 |
| Buy / Hold / Sell | 0 / 2 / 0 |
Earnings (AEMD)
| Next Earnings Date | 2026-06-10 |
|---|---|
| EPS Estimate | USD -2.46 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD -2.45 vs est -2.01 ▼ miss |
| 2025-09-30 | USD -3.74 vs est -1.7 ▼ miss |
| 2025-06-30 | USD -8.5 vs est -7.3 ▼ miss |
| 2025-03-31 | USD -37 vs est -10.9 ▼ miss |
Source: Nexqual, June 10, 2026 at 04:26 UTC.
Financials & Fundamentals (AEMD)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -208.60% |
| Debt / Equity | 6.22 |
| Current Ratio | 5.68 |
| Total Cash | $6.96M |
| Total Debt | $417,522 |
| Free Cash Flow | $-4.54M |
Source: Nexqual, June 10, 2026 at 04:26 UTC.
Financial Health Score (AEMD)
Nexqual rates Aethlon Medical Inc's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 04:26 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $7M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$7M |
| Efficiency | Critical — ROE -209%, ROA -62.9% |
Ownership (AEMD)
| Insider Ownership | +5.03% |
|---|---|
| Institutional Ownership | +6.54% |
| Shares Outstanding | 2.34M |
| Float | 1.24M |
| Short % of Float | +21.14% |
Source: Nexqual, June 10, 2026 at 04:26 UTC.
Leadership (AEMD)
Aethlon Medical Inc is led by James B. Frakes (age 68), CEO, CFO, Chief Accounting Officer, Secretary & Director, per Nexqual as of June 10, 2026 at 04:26 UTC.
| CEO, CFO, Chief Accounting Officer, Secretary & Director | James B. Frakes (age 68) |
|---|
Major Backers & Investors (AEMD)
Notable institutional backers of Aethlon Medical Inc include Fidelity, Ikarian Capital, LLC, Shay Capital LLC, according to Nexqual as of June 10, 2026 at 04:26 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 1.53% |
| Ikarian Capital, LLC | 0.92% |
| Shay Capital LLC | 0.9% |
| Xtx Topco Ltd | 0.85% |
| Morgan Stanley | 0.13% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Geode Capital | 1.55% |
Source: Nexqual, June 10, 2026 at 04:26 UTC.
From Aethlon Medical Inc's Latest SEC 10-K Filing (filed 2025-06-26)
Key Strengths & Strategy (as disclosed to the SEC)
- We also own certain trademarks.   Our success depends in large part on our ability to protect our proprietary technology, including the Hemopurifier product platform, and to operate without infringing the proprietary rights of third parties.
- If we were judicially determined to be infringing on any third-party patent, we could be required to pay damages, alter our products or processes, obtain licenses or cease sales of products or certain activities.   To protect our proprietary medical technologies, including the Hemopurifier product platform and other scientific discoveries, we have a portfolio of over 32 issued patents and pending applications worldwide.
- In addition, the FDA may conduct a preapproval inspection of the manufacturing facility to ensure compliance with the Quality System Regulation, or QSR.
- We rely on a combination of patent, trade secret, copyright and trademark laws, as well as confidentiality agreements, licensing agreements and other agreements, to establish and protect our proprietary rights.
Partnerships
- In several cases, these studies were conducted in collaboration with leading government or non-government research institutes.   The Hemopurifier has previously been studied under FDA and international regulatory frameworks for the treatment of severe SARS-CoV-2 infection.
- Payors may include the Centers for Medicare & Medicaid Services, or CMS, which administers the Medicare program and works in partnership with state governments to administer Medicaid, other government programs and private insurance plans.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| NNVC | NanoViricides, Inc. | USD 1.4 | ▲ 1.45% |
| BNBX | BNB Plus Corp. | USD 0.53 | ▼ 2.78% |
| GOVX | GeoVax Labs, Inc. | USD 1.28 | ▼ 22.42% |
| CFOR | OpGen, Inc. | USD 2 | ▲ 300% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 04:26 UTC. This page is informational and not investment advice.